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Lymphomatoid papulosis (LyP), primary cutaneous anaplastic large T-cell lymphoma (cALCL), and cutaneous
infiltrates of systemic anaplastic large cell lymphoma (sALCL) are CD30-positive lymphoproliferative disorders
of the skin that overlap clinically, histopathologically, immunophenotypically, and genetically but differ
considerably in their prognosis. In particular, lesions of LyP regress spontaneously, whereas those of cALCL and
sALCL persist and may progress and spread to extracutaneous sites. In contrast to patients with cALCL, LyP
patients do not benefit from an aggressive radio- and/or chemotherapeutic approach. We generated a novel
tumor necrosis factor receptor (TNFR)-associated factor 1 (TRAF1) antibody that recognizes a formalin-resistant
epitope (Ber-TRAF1A) and investigated the expression of TRAF1, an intracellular component of TNFR signaling,
in LyP and ALCL. We could show a strong TRAF1 expression in the tumor cells of most LyP cases (42/49, 84%). In
contrast, tumor cells of primary and secondary cALCL revealed TRAF1 expression in only a few cases (3/41, 7%)
as shown for sALCL without skin manifestation. The data indicate that TRAF1 expression reliably distinguishes
LyP from primary or secondary cALCL. This might be of crucial diagnostic importance and has a strong impact
on the treatment decision for patients with cALCL and LyP.
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INTRODUCTION
Primary cutaneous T-cell lymphomas (CTCLs) represent a
heterogeneous group of neoplasms derived from skin-homing
T-cells. Discounting classical mycosis fungoides, primary
cutaneous CD30-positive lymphoproliferations are the most
common entities, comprising approximately 30% of all
CTCLs. This group includes lymphomatoid papulosis (LyP),
primary cutaneous anaplastic large T-cell lymphoma
(cALCL), and borderline cases (Macaulay, 1968; Willemze
et al., 2005).
The two entities have widely overlapping clinical and
histomorphological features but differ in their prognosis. LyP
as well as cALCL can occur at any age and present with
ulcerating lesions and grouped nodules (Willemze et al.,
1982). A histological feature common to both diseases is the
presence of atypical lymphoid CD30-positive T blasts that
sometimes show the morphology of Hodgkin–Reed–Sternberg
cells (Stein et al., 1985). The cells of LyP and ALCL are
genetically characterized by clonal T-cell-receptor gene
rearrangement (Chott et al., 1996; Steinhoff et al., 2002).
However, the two diseases differ considerably in their clinical
course. Although LyP is associated with a favorable 10-year
survival rate of nearly 100%, 10–20% of patients with cALCL
show extracutaneous progression of the lymphoma, including
involvement of the lymph nodes, bone marrow, lungs,
gastrointestinal tract, or central nervous system (Beljaards
et al., 1993; Bekkenk et al., 2000; Liu et al., 2003; Shehan
et al., 2004; Willemze et al., 2005). Approximately 10% of
patients with cALCL die of lymphoma (Beljaards et al., 1993;
Shehan et al., 2004). To avoid assigning patients to an
inappropriate therapeutic regimen, for example, polyche-
motherapy for LyP or clinical observation alone for cALCL, it
is extremely important to distinguish between the two entities
during the early course of the disease. Analysis of the (2;5)-
translocation exhibited by tumor cells in 50% of the primary
systemic ALCL (sALCL) cases is not helpful in clarifying the
differential diagnosis of LyP and cALCL, because the vast
majority of cALCL cases do not carry this translocation
(DeCoteau et al., 1996; Herbst et al., 1997). As cytotoxic
molecules are expressed by the tumor cells of cALCL as well
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as LyP, the detection of a cytotoxic immunophenotype of the
tumor cells do not clarify the differential diagnosis of both
diseases (Boulland et al., 2000). Therefore, more refined
diagnostic criteria are certainly needed.
Recently, we and others have shown that tumor necrosis
factor receptor (TNFR)-associated factor 1 (TRAF1) is differ-
entially expressed in classical Hodgkin’s lymphoma and
sALCL (Du¨rkop et al., 1999, 2003; Zapata et al., 2000;
Murray et al., 2001; Siegler et al., 2003; Rodig et al., 2005).
As a member of the TRAF family, TRAF1 is involved in the
intracellular signal transduction of TNFR family members
without a death domain, for example, CD30 (Du¨rkop et al.,
1992; Dempsey et al., 2003). Although little is known about
the function of TRAF1, it is accepted that TRAF1 is expressed
mainly in activated lymphocytes and that it is strongly
induced by NF-kB (Baker and Reddy, 1998). Therefore, cells
with high NF-kB activity generally express high levels of
TRAF1. It could be induced by several members of the TNFR
family, including CD30, which mediate their intracellular
signaling through NF-kB activation leading to subsequent
TRAF1 induction (Bryce et al., 2006; Du¨rkop et al., 2006).
This study intends to clarify, for the first time, the TRAF1
expression status and its possible impact in the challenging
differential diagnosis of cutaneous CD30-positive lympho-
proliferations. Therefore, we generated a new highly specific
murine TRAF1 mAb, which recognizes a formalin-resistant
epitope. Using this novel mAb, the TRAF1 expression profile
of a large series of cutaneous CD30-positive lymphoproli-
ferations was analyzed and correlated to the clinical
presentation and follow-up. Our findings demonstrate that
the extent of TRAF1 expression distinguishes LyP from both
cALCL and sALCL. TRAF1 staining, thus, provides an
additional criterion for the differential diagnosis and dis-
ease-specific treatment of the different cutaneous CD30-
positive lymphoproliferations.
RESULTS
Generation of TRAF1 antibody
For immunization, we selected a unique part of the TRAF1
molecule not found in other TRAF family members or other
human proteins. BALB/c mice were immunized with this
recombinant TRAF1 fragment. Prerequisites for the selection
of hybridomas were: secretion of an mAb that strongly binds
to the TRAF1 fragment in ELISA, no reactivity with human
albumin in an ELISA, selective TRAF1 binding of several cell
lysates in Western blot (Figure 1), and an immunohistological
pattern strongly resembling the TRAF1 expression pattern, as
previously shown by in situ hybridization and immunohisto-
logy with a commercial available TRAF1 mAb (Du¨rkop et al.,
1999; Zapata et al., 2000). One out of about 200 hybridomas
fulfilled these criteria. The mAb produced by this hybridoma
was selected for further investigations and was named Ber-
TRAF1A.
Clinical and pathologic features of CD30-positive
lymphoproliferations
The study included 90 lymphoma biopsies (49 LyP, 28
cALCL, and 13 sALCL) from 50 patients with cutaneous
CD30-positive lymphoproliferations. The patients were 35
men and 15 women ranging in age from 13 to 78 years
(median age 51 years). The clinical follow-up ranged from 12
to 168 months (Table 1). Characteristics of the patients are
given in detail in Table 1. Biopsies were repeatedly
conducted in 31 patients with LyP and 14 patients with
cALCL. The diagnoses were confirmed in all cases of
repeated biopsies. During the clinical course transformation
of LyP to cALCL was not observed in our patients with LyP.
Although spontaneous regression was a common feature of
our patients with LyP, it was not detected in our 14 patients
with cALCL. Extracutaneous disease was documented in 5/14
(36%) patients with cALCL during the clinical course (at least
6 months after the first diagnosis) including lymph nodes (2/
14, 14%), visceral organs (2/14, 14%), and central nervous
system (1/14, 7%). None of the LyP patients died because of
lymphoproliferation, whereas 3/5 patients with cALCL, which
developed during the clinical course of an extracutaneous
involvement, died because of progression of the lymphoma.
High TRAF1 expression in LyP and low or absent TRAF1
expression in cALCL and sALCL
Based on immunohistological analysis, LyP cases were
subdivided into 41/49 skin lesions (26 patients) of type A
and 8/49 of type C (five patients, Table 2). TRAF1 expression
analysis of 49 cases of LyP revealed strong cytoplasmic
TRAF1 staining (41/49 cases, 84%) in atypical lymphoid
cells. There was no significant difference of TRAF1 staining
between LyP types A and C (Table 2). The same cases were
stained for CD30. In both LyP types, nearly all CD30-positive
lymphocytes express the TRAF1 protein (Figure 2). These
results were supported by immunofluorescence double-
staining showing colocalization of TRAF1 and CD30 in LyP
type A (Figure 2).
Twenty-eight biopsies of cALCL from 14 patients were












Figure 1. Western blot analysis of solubilisates of the KM-H2 and the L428
cell lines with the Ber-TRAF1A mAb. Molecular weight is indicated at the
right margin.
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mostly showed only weak TRAF1 expression (6/28 biopsies,
21%) or no TRAF1 expression at all (21/28 biopsies, 75%).
The tumor cells of 1/28 cALCL case (4%) were strong TRAF1-
positive. Similar results were obtained for the cutaneous
manifestation of sALCL, wherein 11/13 specimens (85%)
were TRAF1-negative and only 2/13 biopsies were TRAF1-
positive (15%). Neither the TRAF1-positive cALCL case nor
both TRAF1-positive sALCL cases exhibit a (2;5)-transloca-
tion. This indicates a similar TRAF1 induction status in sALCL
and cALCL. TRAF1 expression pattern was comparable with
archival lymph node biopsies, obtained from 14 patients with
sALCL without skin manifestation (eight ALCL with t(2;5), six
ALCL without t(2;5); Table 2). The TRAF1 expression was
significantly higher in LyP than in primary cALCL and sALCL
(Po7107). Neither cALCL nor sALCL showed a significant
difference of TRAF1 expression with regard to their t(2;5)
status. There was no significant difference in the TRAF1
staining of patients with multiple biopsies.
Interestingly, in all subtypes of cutaneous CD30-positive
lymphoproliferations the surrounding CD30-negative cells
showed complete absence of TRAF1 staining, enabling a
clear differentiation and interpretation of the CD30-positive
tumor cells (Figure 2).
The commercial available TRAF1 mAb H3 was compared
in 22 cases of CD30-positive lymphoproliferations with the
Ber-TRAF1A mAb by immunohistology. In principle, both
mAbs generated the same staining pattern in 10 cases of
cALCL, four cases of sALCL, six cases of LyP type A, and two
cases of LyP type C, but the Ber-TRAF1A mAb seems to better
differentiate between low and high expression levels of
TRAF1 than the H3 mAb.
DISCUSSION
Primary CD30-positive cALCL and LyP show many over-
lapping clinical, histological, immunophenotypic, and genetic
features. Owing to the difficult differential diagnosis, the
Table 1. Clinical characteristics of patients
Characteristics LyP cALCL sALCL
Number 31 14 5
Sex
Male 19 10 5
Female 12 4 0
Age (years)
Median 45.5 65.4 43.0
Range 12–78 16–81 18–67
Extent of skin lesion
Solitary 4 (13%) 6 (43%) 0 (0%)
Regional 12 (39%) 5 (36%) 4 (80%)
Generalized 15 (48%) 3 (8%) 1 (20%)
Involved extracutaneous sites1
No extracutaneous involvement 31 (100%) 9 (64%) 0 (0%)
Lymph nodes 0 (0%) 2 (14%) +
Visceral organs 0 (0%) 2 (14%) 2 (40%)
CNS 0 (0%) 1 (7%) 0 (0%)
Initial therapy
Psoralen UV-A/UV-B 12 (39%) 2 (14%) 0 (0%)
Excision 5 (16%) 6 (43%) 0 (0%)
Radiotherapy 0 (0%) 2 (14%) 0 (0%)
Single agent chemotherapy (methotrexat) 6 (19%) 4 (28%) 0 (0%)
Multiagent chemotherapy 0 (0%) 0 (0%) 5 (100%)
None/topical steroids 8 (26%) 0 (0%) 0 (0%)
Follow-up (months)
Median 43.7 37.1 43.4
Range 12–168 14–98 27–66
Clinical course
Complete remission 14 (45%) 2 (14%) 2 (40%)
Partial remission 17 (55%) 5 (36%) 1 (20%)
Progressive disease 0 (0%) 7 (50%) 2 (40%)
Current status
No evidence of disease 13 (42%) 2 (14%) 2 (40%)
Alive with disease 17 (55%) 9 (64%) 2 (40%)
Died of lymphoma 0 (0%) 3 (8%) 1 (20%)
Died of other cause 1 (3%) 0 (0%) 0 (0%)
Involvement of extracutaneous sites more than 6 months after diagnosis;
+sALCL evolved primary in the lymph node.
cALCL, primary cutaneous anaplastic large cell lymphoma; sALCL:
systemic anaplastic large cell lymphoma with secondary involvement of
skin; CNS, central nervous system; LyP, lymphomatoid papulosis.
Table 2. Summary of TRAF1 immunohistochemical
staining pattern
Diagnosis N TRAF1 (+) TRAF1 (7) TRAF1 ()
LyP 49 41/49 (84%) 5/49 (10%) 3/49 (6%)
LyP-A 41 35/41 (85%) 3/41 (7%) 3/41 (7%)
LyP-C 8 6/8 (75%) 2/8 (25%) 0/8 (0%)
cALCL 28 1/28 (4%) 6/28 (21%) 21/28 (75%)
sALCL 13 2/13 (15%) 0/13 (0%) 11/13 (85%)
nALCL 14 2/14 (14%) 0/14 (0%) 12/14 (86%)
cALCL, primary cutaneous anaplastic large cell lymphoma; sALCL,
secondary cutaneous infiltration of systemic anaplastic large cell
lymphoma; nALCL, systemic anaplastic large cell lymphoma (lymph
node) without cutaneous infiltration; LyP, lymphomatoid papulosis;
TRAF1, tumor necrosis factor receptor-associated factor 1, (+), strong
reactivity, that is, intensive and confluent staining of the entire cytoplasm
in more than 80% of the tumor cells; 7, weak or moderate TRAF1
staining, that is, faint, sometimes grainy, TRAF1 staining of parts of the
cytoplasm in less than 80% of the tumor cells; (), no TRAF1 staining of
tumor cells.
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recent WHO-EORTC classification included a ‘‘borderline
group’’ for cases in which a definitive distinction between
cALCL and LyP cannot be done despite thorough clinical and
pathological assessment. Owing to these diagnostical diffi-
culties, LyP patients diagnosed as having a ‘‘CD30-positive
lymphoma’’ are routinely treated with multiagent chemother-
apy by physicians unaware of the spectrum of LyP.
Unfortunately, skin relapses of LyP occur very frequently
during or shortly after systemic chemotherapy. That gives the
false impression of a highly aggressive T-cell lymphoma
requiring even more aggressive chemotherapy (Paulli et al.,
1995). On the other hand, insufficient treatment of cALCL
potentially leads to a fatal outcome (Shehan et al., 2004).
Therefore, objective criteria are needed to effectively
differentiate between LyP and cALCL patients.
This study presents the first TRAF1 expression data
in cutaneous CD30-positive lymphoproliferations. TRAF1
represents a possible marker to differentiate between LyP
and cALCL. We developed a highly specific immunohistolo-
gical routinely applicable murine mAb corresponding to a
characteristic domain of the TRAF1 molecule that is not
shared by other molecules, not even by those of other TRAF
family members. The specificity of this TRAF1 mAb was
confirmed by ELISA, Western blot analysis, and numerous
immunohistological investigations. Its staining pattern is
identical to the one previously described for TRAF1 expres-
sion by in situ hybridization (Du¨rkop et al., 1999). Clinically
and histopathologically well-defined patients with cutaneous
CD30-positive lymphoproliferations were investigated to
assess both the feasibility of applying TRAF1 expression and
its diagnostic value in routine practice. The commercial
available TRAF1 mAb H3 generated the same staining pattern
as the Ber-TRAF1A mAb. However, because of better












Figure 2. Immunohistological staining pattern of the Ber-TRAF1A mAb in cases of LyP type A (LyP-A), LyP type C (LyP-C), and cALCL in comparison with
CD30 staining and hematoxylin–eosin staining. The immunhistological expression of TRAF1 and CD30 in LyP type A was supplemented by confocal
microscopy (see insets of the CD30 and TRAF1 staining in LyP-A row). The colocalization of TRAF1 (red) and CD30 (green) expression in LyP-A is indicated
in the picture at the right margin of the LyP-A row by a yellow label. Nuclei were stained by TOTO-3 (blue). Bars in the main pictures represent 50 mm,
whereas the bars in the insets indicate 20mm.
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levels, the latter mAb seems to be more suitable for the
differentiation of cutaneous manifestations of ALCL and LyP.
An analysis of cutaneous CD30-positive lymphoprolifera-
tions clearly demonstrates a difference of TRAF1 expression
between LyP and cALCL. TRAF1 is highly expressed in LyP.
This includes LyP type C cases, which are hard to be
differentiated from cALCL and cutaneous manifestations of
sALCL because of the large sheets of CD30-positive tumor
cells by histology and immunohistology. Double-staining
immunofluorescence revealed colocalization of TRAF1 and
CD30 in the LyP tumor cells, whereas TRAF1 expression was
absent in the surrounding T- and B-cells. In contrast to CD30-
positive cells of LyP, cALCL tumor cells were almost TRAF1-
negative.
TRAF1 is upregulated by NF-kB activation (Murray et al.,
2001; Dempsey et al., 2003; Bryce et al., 2006). Therefore,
differential TRAF1 expression in LyP and ALCL could be
explained by varying NF-kB activity in the tumor cells of both
entities. This assumption corresponds well to the finding of
low NF-kB activity in unstimulated cALCL and sALCL cell
lines (Levi et al., 2000; Du¨rkop et al., 2006). Accordingly, the
strong TRAF1 expression in LyP tumor cells might indicate
that these cells share the high NF-kB activity with the
classical Hodgkin lymphoma tumor cells (Du¨rkop et al.,
2003; Du¨rkop et al., 2006). However, exact data about the
NF-kB activity in this tumor are not available, which is at
least partially due to the lack of LyP cell lines. Owing to the
striking differences of TRAF1 expression between LyP and
cALCL, we would speculate that the activation of TRAF1
could play a role in the mechanism(s) of the clinically
obvious spontaneous regression in LyP in contrast, to the
persistence and progression of tumors in cALCL, respectively.
However, in contrast to our cALCL series spontaneous
regression is also reported in a part of cALCL (Paulli et al.,
1995; Willemze et al., 2005). In these cases, analysis of
TRAF1 expression would be interesting. TRAF1 function is
complex and not completely understood. However, it seems
to be possible that TRAF1 influences the sensitivity of cells to
apoptosis (Cha et al., 2003; Du¨rkop et al., 2003). Further
analysis of TRAF1 expression in conjunction with the
phosphorylation status of NF-kB and its inhibitors might
elucidate the biology of cutaneous CD30-positive lympho-
proliferations.
In conclusion, strong TRAF1 expression is almost restricted
to CD30-positive cells in LyP, indicating that its over-
expression in LyP is not only of pathogenetic relevance but
might also be a new marker for the differential diagnosis of
LyP and cALCL. Determination of the TRAF1 expression
status might enable the initiation of disease-specific manage-
ment in patients with cutaneous CD30-positive lymphopro-
liferations.
MATERIALS AND METHODS
Generation and characterization of the TRAF1 antibody
TRAF1 cDNA (acc. no. U19261) was amplified from L428 mRNA by
reverse transcription PCR at nucleotide positions 418–774 using the
oligonucleotide pair GAA TTC TGC CCT GGA GCA GAA CCT
G/GAA TTC GCG CAA GCT CTG CTC CAG C (EcoRI sites are
underlined). This TRAF1 cDNA-coding sequence for the amino-acid
residues 140–258 was cloned into the expression vector pRSET/E
(Invitrogen, Carlsbad, CA). After expression in Escherichia coli
(BL21pLysS, Invitrogen), the recombinant protein carrying a
N-terminal 6 His-tag was purified by affinity chromatography
and subsequent gel filtration chromatography. BALB/c mice were
immunized with the TRAF1 fragment. The TRAF1 antibody titer
was determined in mouse tail-vein blood by ELISA with TRAF1
fragment-coated 96-well plates according to standard procedures
(Ausubel et al., 2006). After mice developed a high titer against
TRAF1, spleenocytes were isolated and fused with the murine
myeloma cell line NS-1 (Ausubel et al., 2006). Hybridoma super-
natants were harvested and tested by ELISA using TRAF1-coated and,
as a negative control, albumin-coated plates. Reactivity of the TRAF1
mAbs was verified by Western blot analysis of the classical Hodgkin
lymphoma cell lines L1236, L428, and KM-H2 as well as the sALCL
cell line Karpas 299 (Drexler, 2001). To ensure that the new TRAF1
mAb depicts the typical TRAF1 expression pattern (Du¨rkop et al.,
1999; Zapata et al., 2000; Siegler et al., 2003; Bryce et al., 2006), we
performed immunohistological examinations of 10 tonsils and more
than 200 lymphoma cases, including classical Hodgkin lymphoma,
different subtypes of diffuse large B cell lymphoma, sALCL, follicular
lymphoma, lymphocytic lymphoma, mantle cell lymphoma, an-
gioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma,
and marginalzone lymphoma as well as lymphoblastic T- and B-cell
lymphoma. All cases were drawn from the Institute of Pathology,
Charite´, Campus Benjamin Franklin.
Patients
The study included a total of 90 skin samples stemming from 50
clinically well-characterized patients with CD30-positive cutaneous
lymphoproliferations. All patients were treated and clinically
followed up by the Department of Dermatology, Charite´, Berlin.
The CD30-positive cutaneous lymphoproliferations were classified
based on the histopathological features, supplemented by additional
clinical information according to the recent WHO-EORTC classifi-
cation of lymphoid neoplasms (Willemze et al., 2005). This
collective consisted of 31 patients with LyP, 14 patients with cALCL,
and five patients presenting with a secondary skin manifestation of
sALCL. Two of these sALCL cases showed a (2;5)-translocation.
LyP was defined as recurrent nodular eruptions with evidence of
spontaneous regression of all lesions and histological features
consistent with LyP. cALCL was defined as nodules or tumor lesions
with histological features typical for cALCL and no evidence of
extracutaneous manifestation at initial presentation (Willemze et al.,
2005). According to the amount of CD30-positive atypical cells, LyP
cases were subdivided into three histological types designated as
A(scattered CD30-positive cells), B (absence of CD30-positive cells),
and C (sheets of CD30-positive cells histologically undistinguishable
from cALCL) (Willemze et al., 1982). As LyP type C histologically
and immunohistologically often resembles cALCL, we verified the
differential diagnosis between these entities according to the clinical
findings of spontaneous regression and skin eruption. We intended
to clarify the differential diagnosis between the LyP subtypes
containing CD30-positive cells and cALCL. Therefore, we restricted
the study to cases of LyP types A and C.
Diagnosis and staging of patients were completed after a
comprehensive history and physical examination, complete blood
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cell counts including peripheral blood smears for Se´zary cells,
CD4:CD8 ratio, a general chemistry panel including serum lactate
dehydrogenase, a chest X-ray, and an ultrasound of the abdomen
and peripheral lymph nodes. Suspected visceral involvement was
evaluated by imaging studies or by tissue and bone marrow biopsies,
when indicated. Characteristics to the patients including extent of
skin lesions, occurrence of extracutaneous disease, treatments,
clinical course, and outcome were recorded for each patient
(Table 1). Each skin sample was investigated twice by T-cell
receptor-g PCR and Genescan analysis (Lukowsky, 2003). The
consent of the patients was obtained to use their biopsies. The
ethical committee of the Charite´ (Universita¨tsmedizin, Berlin) has
approved the described studies. The study was conducted according
to the Declaration of Helsinki Principles.
Immunohistology
All skin and lymph node samples were examined by hematox-
ylin–eosin staining and immunohistological staining (TRAF1 (Ber-
TRAF1A and H3, latter: Santa Cruz, Heidelberg, Germany)), CD4
(1F6; Novocastra, Newcastle upon Tyne, UK), (DAKO, Glostrup,
Denmark) CD3 (polyclonal CD3), CD8 (C8–144), CD30 (Ber-H2),
ALK1, and ALKc (Cordell et al., 1984). To unmask antigen epitopes,
all sections were pretreated by high-pressure cooking (10 mM citrate
buffer, pH 6.0). For TRAF1/CD30 double-fluorescence staining,
TRAF1 was detected by alkaline phosphatase monoclonal anti-
alkaline phosphatase method (Cordell et al., 1984) and CD30 by
anti-mouse Cy2 sera (Dianova, Hamburg, Germany). Nuclear
staining was performed by TOTO-3 (Molecular Probes, Paisley,
UK) and the fluorescence staining was evaluated by a confocal
microscope (Leitz, Wetzlar, Germany).
Reactivity for TRAF1 was determined and scored independently
by two pathologists. Intensity of staining for TRAF1 was scored as
follows: (þ ) strong staining, that is, intensive and confluent staining
of the entire cytoplasm in more than 80% of the tumor cells; (þ /)
weak or moderate staining, that is, faint, sometimes grainy, staining
of parts of the cytoplasm in less than 80% of the tumor cells; () no
staining of tumor cells.
Statistical analysis
Statistical analysis was performed using the w2 test.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by the Deutsche Forschungsgemeinschaft (SFB 366).
We thank Linda El-Ahmad, Ines Puschendorf, and Edda von der Wall for their
outstanding technical assistance. We also thank Dr M.A. Kadin for critical
reading of this paper.
REFERENCES
Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA et al.
(2006) (eds) Current Protocols in Molecular Biology. New York: Wiley
Interscience
Baker SJ, Reddy EP (1998) Modulation of life and death by the TNF receptor
superfamily. Oncogene 17:3261–70
Bekkenk MW, Geelen FAMJ, van Voorst Vader PC, Heule F, Geerts ML, van
Vloten WA et al. (2000) Primary and secondary cutaneous CD30+
lymphoproliferative disorders: a report from the Dutch Cutaneous
Lymphoma Group on the long-term follow-up data of 219 patients and
guidelines for diagnosis and treatment. Blood 95:3653–61
Beljaards RC, Kaudewitz P, Berti E, Gianotti R, Neumann C, Rosso R
et al. (1993) Primary cutaneous CD30-positive large cell lymphoma:
definition of a new type of cutaneous lymphoma with a favorable
prognosis. A European multicenter study on 47 cases. Cancer
71:2097–104
Boulland M-L, Wechsler J, Bagot M, Pulford K, Kanavaros P, Gaulard P (2000)
Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid
papulosis frequently express cytotoxic proteins. Histopathology
36:136–44
Bryce PJ, Oyoshi MK, Kawamoto S, Oettgen HC, Tsitsikov EN (2006)
TRAF1 regulates Th2 differentiation, allergic inflammation and nuclear
localization of the Th2 transcription factor, NIP45. Int Immunol
18:101–11
Cha GH, Cho KS, Lee JH, Kim M, Kim E, Park J et al. (2003) Discrete functions
of TRAF1 and TRAF2 in Drosophila melanogaster mediated by c-Jun N-
terminal kinase and NF-kB-dependent signaling pathways. Mol Cell Biol
23:7982–91
Chott A, Vonderheid EC, Olbricht S, Miao NN, Balk SP, Kadin ME (1996) The
dominant T cell clone is present in multiple regressing skin lesions and
associated T cell lymphomas of patients with lymphomatoid papulosis. J
Invest Dermatol 106:696–700
Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S et al.
(1984) Immunoenzymatic labelling of monoclonal antibodies using
immune complexes of alkaline phosphatase and monoclonal anti-
alkaline phosphatase (APAAP complexes). J Histochem Cytochem
32:219–24
DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME (1996) The t(2;5)
chromosomal translocation is not a common feature of primary
cutaneous CD30+ lymphoproliferative disorders: comparison
with anaplastic large cell lymphoma of nodal origin. Blood 87:
3437–3441
Dempsey PW, Doyle SE, He JQ, Cheng G (2003) The signaling adaptors and
pathways activated by TNF superfamily. Cytokine Growth Factor Rev
14:193–209
Drexler HG (2001) (ed) The Leukemia-Lymphoma Cell Line Facts Book. San
Diego: Academic Press
Du¨rkop H, Foss HD, Demel G, Klotzbach H, Hahn C, Stein H (1999) Tumor
necrosis factor receptor-associated factor 1 is overexpressed in Reed–-
Sternberg cells of Hodgkin’s disease and Epstein – Barr virus-transformed
lymphoid cells. Blood 93:617–23
Du¨rkop H, Hirsch B, Hahn C, Foss HD, Stein H (2003) Differential expression
and function of A20 and TRAF1 in Hodgkin’s lymphoma and anaplastic
large cell lymphoma and their induction by CD30 stimulation. J Pathol
200:229–39
Du¨rkop H, Hirsch B, Hahn C, Stein H (2006) cIAP2 is highly expressed in
Hodgkin’s–Reed–Sternberg cells and inhibits apoptosis by interfering
with constitutively active caspase-3. J Mol Med 84:132–41
Du¨rkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H (1992)
Molecular cloning and expression of a new member of the nerve growth
factor receptor family that is characteristic for Hodgkin’s disease. Cell
68:421–7
Herbst H, Sander C, Tronnier M, Kutzner H, Hugel H, Kaudewitz P (1997)
Absence of anaplastic lymphoma kinase (ALK) and Epstein–Barr virus
gene products in primary cutaneous anaplastic large cell lymphoma and
lymphomatoid papulosis. Br J Dermatol 137:680–6
Levi E, Wang Z, Petrogiannis-Haliotis T, Pfeifer WM, Kempf W, Drews R et al.
(2000) Distinct effects of CD30 and Fas signaling in cutaneous anaplastic
lymphomas: a possible mechanism for disease progression. J Invest
Dermatol 115:1034–40
Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH (2003) CD30+
cutaneous lymphoproliferative disorders: the Stanford experience in
lymphomatoid papulosis and primary cutaneous anaplastic large cell
lymphoma. J Am Acad Dermatol 49:1049–58
Lukowsky A (2003) Clonality analysis by T-cell receptor gamma PCR and
high-resolution electrophoresis in the diagnosis of cutaneous T-cell
lymphoma (CTCL). Methods Mol Biol 218:303–20
www.jidonline.org 1903
C Assaf et al.
TRAF1 in Cutaneous CD30þ Lymphoproliferations
Macaulay WL (1968) Lymphomatoid papulosis. A continuing self-healing
eruption, clinically benign – histologically malignant. Arch Dermatol
97:23–30
Murray PG, Flavell JR, Baumforth KR, Toomey SM, Lowe D, Crocker J et al.
(2001) Expression of the tumour necrosis factor receptor-associated
factors 1 and 2 in Hodgkin’s disease. J Pathol 194:158–64
Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C et al. (1995) CD30/Ki-1-
positive lymphoproliferative disorders of the skin – clinicopathologic
correlation and statistical analysis of 86 cases: a multicentric study from
the European Organization for Research and Treatment of Cancer
Cutaneous Lymphoma Project Group. J Clin Oncol 13:1343–54
Rodig SJ, Savage KJ, Nguyen V, Pinkus GS, Shipp MA, Aster JC et al. (2005)
TRAF1 expression and c-Rel activation are useful adjuncts in distinguish-
ing classical Hodgkin’s lymphoma from a subset of morphologically or
immunophenotypically similar lymphomas. Am J Surg Pathol
29:196–203
Shehan JM, Kalaaji AN, Markovic SN, Ahmed I (2004) Management of
multifocal primary cutaneous CD30 anaplastic large cell lymphoma.
J Am Acad Dermatol 51:103–10
Siegler G, Kremmer E, Gonnella R, Niedobitek G (2003) Epstein – Barr virus
encoded latent membrane protein 1 (LMP1) and TNF receptor associated
factors (TRAF): colocalisation of LMP1 and TRAF1 in primary EBV
infection and in EBV associated Hodgkin’s lymphoma. Mol Pathol
56:156–61
Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen G et al.
(1985) The expression of the Hodgkin’s disease associated antigen Ki-1
in reactive and neoplastic lymphoid tissue: evidence that Reed–Sternberg
cells and histiocytic malignancies are derived from activated lymphoid
cells. Blood 66:848–58
Steinhoff M, Hummel M, Anagnostopoulos I, Kaudewitz P, Seitz V, Assaf C
et al. (2002) Single-cell analysis of CD30+ cells in lymphomatoid
papulosis demonstrates a common clonal T-cell origin. Blood
100:578–84
Willemze R, Jaffe´ ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. (2005)
WHO-EORTC classification for cutaneous lymphomas. Blood
105:3768–85
Willemze R, Meyer CJ, van Vloten WA, Scheffer E (1982) The clinical and
histological spectrum of lymphomatoid papulosis. Br J Dermatol
107:131–44
Zapata JM, Krajewska M, Krajewski S, Kitada S, Welsh K, Monks A et al.
(2000) TNFR-associated factor family protein expression in normal
tissues and lymphoid malignancies. J Immunol 165:5084–96
1904 Journal of Investigative Dermatology (2007), Volume 127
C Assaf et al.
TRAF1 in Cutaneous CD30þ Lymphoproliferations
